- Home
- TSHA vs PACB Comparison
TSHA vs PACB Comparison
Compare TSHA & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- PACB
- Stock Information
- Founded
- TSHA 2019
- PACB 2000
- Country
- TSHA United States
- PACB United States
- Employees
- TSHA N/A
- PACB N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- TSHA Health Care
- PACB Industrials
- Exchange
- TSHA Nasdaq
- PACB Nasdaq
- Market Cap
- TSHA 403.7M
- PACB 452.1M
- IPO Year
- TSHA 2020
- PACB 2010
- Fundamental
- Price
- TSHA $2.06
- PACB $1.60
- Analyst Decision
- TSHA Strong Buy
- PACB Buy
- Analyst Count
- TSHA 8
- PACB 15
- Target Price
- TSHA $6.63
- PACB $2.92
- AVG Volume (30 Days)
- TSHA 6.0M
- PACB 11.4M
- Earning Date
- TSHA 11-13-2024
- PACB 11-07-2024
- Dividend Yield
- TSHA N/A
- PACB N/A
- EPS Growth
- TSHA N/A
- PACB N/A
- EPS
- TSHA N/A
- PACB N/A
- Revenue
- TSHA $9,915,000.00
- PACB $173,147,000.00
- Revenue This Year
- TSHA N/A
- PACB N/A
- Revenue Next Year
- TSHA N/A
- PACB $25.88
- P/E Ratio
- TSHA N/A
- PACB N/A
- Revenue Growth
- TSHA N/A
- PACB 2.14
- 52 Week Low
- TSHA $1.19
- PACB $1.16
- 52 Week High
- TSHA $4.32
- PACB $10.65
- Technical
- Relative Strength Index (RSI)
- TSHA 55.32
- PACB 36.99
- Support Level
- TSHA $1.19
- PACB $1.82
- Resistance Level
- TSHA $2.63
- PACB $2.66
- Average True Range (ATR)
- TSHA 0.24
- PACB 0.34
- MACD
- TSHA 0.08
- PACB -0.08
- Stochastic Oscillator
- TSHA 60.42
- PACB 3.02
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.